Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II randomized double-blind placebo-controlled study of HDM3019 in moderate-to-severe active rheumatoid arthritis
CTR20251966Phase 2Active
- Sponsor
- 杭州中美华东制药有限公司 (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.)
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HDM3019 in rheumatoid arthritis (RA), sponsored by 杭州中美华东制药有限公司 (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.). Started May 2025; status: active.
02
Drugs
HDM3019
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20251966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251966.